Fusidic Acid Monotherapy

Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing.

The level of resistance to fusidic acid among community methicillin-susceptible Staphylococcus aureus (MSSA) isolates in the UK and prescriptions for fusidic acid have both doubled over the past 6 years. It is hypothesized that selective pressure arising from topical use of fusidic acid in the community accounts for this increase. A significant correlation was found between prescribing of fusid...

Staphylococcal bacteraemia, fusidic acid, and jaundice.

Fusidic acid was used to treat 131 out of 250 patients with staphylococcal bacteraemia over 10 years. Other antimicrobial agents were given to the 119 remaining patients. Thirty-seven patients were already jaundiced before antibiotic treatment was started. Jaundice developed during treatment in 38 out of 112 patients given fusidic acid (34%) and in two out of 101 patients given other antimicrob...

Fusidic acid-induced leukopenia and thrombocytopenia.

Fusidic acid is an active agent against a wide variety of gram-positive bacteria, and it has been increasingly used in methicillin-resistant Staphylococcus aureus infection. The major adverse effects are mild gastrointestinal discomfort and diarrhea. The hematological side effects such as granulocytopenia and thrombocytopenia have been rarely reported in western countries, but have not been doc...

On Fusidic Acid Resistance in Staphylococcus Aureus

Introduction: fusidic acid enters the United States.

The emergence of infections due to communityassociated methicillin-resistant Staphylococcus aureus (MRSA) in the United States (and elsewhere in the world) during the past decade has brought the rather pedestrian spectrum of acute bacterial skin and skin structure infections (ABSSSIs) to a new level of concern [1]. Previously recommended oral antibiotics, such as oxacillin, cloxacillin, dicloxa...